Még nem toboroz
Safety and Efficacy of a STOPping Strategy Versus Classical Maintenance Dose of JAK Inhibitors in Deep Remission Patients With Ulcerative Colitis
NCT07718529· 4. fázis· Assistance Publique Hopitaux De Marseille· Forrás
Még nem toboroz
FILOCLL017 - NEVOTAL : Nemtabrutinib in addition to Venetoclax-Obinutuzumab in chronic lymphocytic leukemia (CLL) / small lymphocytic leukemia (SLL) patients with TP53 ALterations
2026-525763-40-00· 2. fázis· French Innovative Leukemia Organization (F.I.L.O.).· Forrás
Még nem toboroz
Therapeutic Drug Monitoring-baSed adalimuMab De-escalatiOn in nOn-infecTious cHronic Uveitis
NCT06390436· 4. fázis· Centre Hospitalier Universitaire de Saint Etienne· Forrás
Még nem toboroz
FirST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised Controlled Trial
NCT07576452· 4. fázis· University Hospital, Clermont-Ferrand· Forrás
Még nem toboroz
Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
NCT07739459· 2. fázis· The Lymphoma Academic Research Organisation· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
NCT07541170· 3. fázis· Hoffmann-La Roche· Forrás
Még nem toboroz
OBINUSS - A trial to evaluate a new drug in systemic sclerosis: obinutuzumab.
2025-524003-68-00· 2. fázis· Assistance Publique Hopitaux De Paris· Forrás
Még nem toboroz
Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL).
NCT07624799· 2. fázis· French Innovative Leukemia Organisation· Forrás
Fut, nem toboroz
A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small cell lung cancer.
2023-503298-39-00· 3. fázis· AstraZeneca AB· Forrás
Még nem toboroz
A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL
2024-516570-30-00· 2. fázis· Centre Hospitalier De Versailles· Forrás
Toboroz
Trial assessing fianlimab plus cemiplimab plus chemotherapy or cemiplimab plus chemotherapy in patients with pleural mesothelioma
2024-519208-29-00· 2. fázis· Intergroupe Francophone De Cancerologie Thoracique· Forrás
Toboroz
A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
NCT06931717· 3. fázis· ETOP IBCSG Partners Foundation· Forrás
Toboroz
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
NCT07098338· 2. fázis· AstraZeneca· Forrás
Toboroz
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
NCT06767514· 3. fázis· Summit Therapeutics· Forrás
Toboroz
Beta-blOckers discoNtinuation in patients presenting heart FaIlure with REcovered left ventricular ejection fraction
2023-508798-94-00· 3. fázis· Assistance Publique Hopitaux De Paris· Forrás
Toboroz
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
NCT06717347· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone
NCT06561854· 3. fázis· Assistance Publique - Hôpitaux de Paris· Forrás
Toboroz
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
NCT06627647· 3. fázis· AstraZeneca· Forrás
Toboroz
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738· 3. fázis· AstraZeneca· Forrás
Még nem toboroz
Safety and Efficacy of Apixaban Versus Warfarin in Peritoneal Dialysis Patients With Non Valvular Atrial Fibrillation: a Prospective, Randomised, Open-label, Blinded End-point Trial (APIDP2)
NCT06045858· 3. fázis· University Hospital, Caen· Forrás
Fut, nem toboroz
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06417814· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Capsules Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
2024-510965-41-00· 3. fázis· AbbVie Deutschland GmbH & Co. KG· Forrás
Toboroz
Apixaban/rivaroxaban Versus Aspirin for primary prevention of thrombo-embolic complications in JAK2V617F-positive myeloproliferative neoplasms
2024-515362-13-00· 2/3. fázis· Centre Hospitalier Regional Et Universitaire De Brest· Forrás
Fut, nem toboroz
Treatment of microstellite stable metastatic colorectal cancer presenting high immune infiltrate with chemotherapy (XELOX or FOLFOX Bevacizumab) and
immunotherapy ( Pembrolizumab)
NCT04262687· 2. fázis· Fondation Franc.Cancerologie Digestive· Forrás
Toboroz
Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis
NCT05841758· 4. fázis· Hospices Civils de Lyon· Forrás
Toboroz
Colchicine Versus Placebo in Acute Myocarditis Patients
NCT05855746· 3. fázis· Assistance Publique - Hôpitaux de Paris· Forrás
Toboroz
“Randomized controlled multicenter study comparing efficacy and safety of adalimumab to that of mycophenolate mofetil in steroid dependent non-infectious uveitis” - FOCUS
2023-505112-38-00· 4. fázis· Assistance Publique Hopitaux De Paris· Forrás
Toboroz
FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum
NCT06393816· 2. fázis· Centre Leon Berard· Forrás
Contact: Nicolas CLOAREC, MD
Toboroz
DVT Burden and the Risk of Post-thrombotic Syndrome
NCT06385353· Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer· Forrás
Contact: Olivier GRAS
Fut, nem toboroz
MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal antibody plus chemotherapy in subjects with previously untreated FLIPI 2-5 follicular lymphoma
2023-505436-35-00· 3. fázis· Lysarc· Forrás
Toboroz
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
NCT06345729· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06158841· 3. fázis· AbbVie· Forrás
Toboroz
UVB: treatment of UVeitis in Behçet’s diseases with biologic
2024-513371-41-00· 2. fázis· Assistance Publique Hopitaux De Paris· Forrás
Fut, nem toboroz
TocilizuMab discontinuAtion in GIant Cell Arteritis
2023-505515-21-00· 3. fázis· Centre Hospitalier Universitaire De Dijon· Forrás
Fut, nem toboroz
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
NCT06191744· 3. fázis· Genmab· Forrás
Toboroz
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
NCT06149286· 3. fázis· Regeneron Pharmaceuticals· Forrás
Toboroz
Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC
NCT05718323· 2. fázis· ETOP IBCSG Partners Foundation· Forrás
Toboroz
A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer
NCT05639413· UNICANCER· Forrás
Contact: Emilie BRUMENT
Toboroz
CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics
NCT05260528· 2. fázis· Centre Hospitalier Universitaire de Nice· Forrás
Fut, nem toboroz
Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy
NCT05781308· 2. fázis· Intergroupe Francophone de Cancerologie Thoracique· Forrás
Toboroz
Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia
NCT05338190· 3. fázis· Assistance Publique - Hôpitaux de Paris· Forrás
Toboroz
Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
NCT05181735· 1/2. fázis· Groupe Francophone des Myelodysplasies· Forrás
Toboroz
De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction
NCT05255302· 2/3. fázis· Intergroupe Francophone de Cancerologie Thoracique· Forrás
Toboroz
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
NCT05061550· 2. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Intravenous Immunoglobulin plus oral prednisone or high-dose dexamethasone, for adults with immune thrombocytopenia (ITP) with moderate and severe bleeding: a randomized, multicentre trial (IVIORDEX).
NCT04968899· 3. fázis· Assistance Publique Hopitaux De Paris· Forrás
Toboroz
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT04928846· 3. fázis· AbbVie· Forrás
Fut, nem toboroz
OASIS II - A randomized phase II trial evaluating Ibrutinib plus CD20 Ab and Ibrutinib-Venetoclax plus CD20 Ab in patients with untreated mantle cell lymphoma
2024-512634-15-00· 1/2. fázis· LYSARC· Forrás
Fut, nem toboroz
Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older
NCT04974216· 2. fázis· The Lymphoma Academic Research Organisation· Forrás
Fut, nem toboroz
Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).
NCT04751877· 3. fázis· Poitiers University Hospital· Forrás
Toboroz
The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma
NCT04803994· 3. fázis· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Forrás
Showing 50 of 60.